menu
    • menu
    [{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Metyrapone","moa":"CYP11B1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Metyrapone","moa":"||CYP11B1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Foundation for a Smoke Free World | Rose Research Center | Segal Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ Foundation for a Smoke Free World | Rose Research Center | Segal Trials","highestDevelopmentStatusID":"7","companyTruncated":"Embera NeuroTherapeutics \/ Foundation for a Smoke Free World | Rose Research Center | Segal Trials"}]

    Find Clinical Drug Pipeline Developments & Deals by Embera NeuroTherapeutics

    Menu

    Embera NeuroTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Foundation for a Smoke Free World | Rose Research Center | Segal Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of EMB-001 as a Potential Smoking Cessation Treatment

                            Details : EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Tobacco Use Disorder.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            June 22, 2021

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Foundation for a Smoke Free World | Rose Research Center | Segal Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metyrapone,Oxazepam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder

                            Details : The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocain...

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 31, 2020

                            Lead Product(s) : Metyrapone,Oxazepam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

                            Details : EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cocaine-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 06, 2020

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

                            Details : EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            January 19, 2018

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

                            Details : EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 05, 2016

                            Lead Product(s) : EMB-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Embera NeuroTherapeutics

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metyrapone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

                            Details : Metyrapone is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            April 02, 2015

                            Lead Product(s) : Metyrapone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth